Actively Recruiting
Influence of Pre-diagnostic Estrogen Fluctuations on the Development of Prolactin-Secreting Macroadenomas or Microadenomas: A Comparative Study Conducted at Hôpital Louis Pradel
Led by Hospices Civils de Lyon · Updated on 2026-01-22
180
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Prolactinomas are the most common type of pituitary tumors, affecting about 50 people per 100,000. They may cause symptoms due to hormone overproduction, like galactorrhea and infertility, or from tumor size pressing on nearby areas, causing headaches and vision problems. This research is comparing women with larger prolactin-secreting tumors (macroadenomas) to those with smaller ones (microadenomas) to understand if estrogen exposure before diagnosis influences tumor size. The study involves two groups of women diagnosed between 2013 and 2023 with either macroprolactinomas or microprolactinomas, all followed at a hospital in Lyon. Participants will complete a detailed questionnaire about their hormone and reproductive history, either by phone or mail, to collect information on estrogen exposure and other factors potentially related to tumor development. Participants will provide data mainly through questionnaires, with medical records reviewed as needed. Researchers will assess exposures such as hormonal contraceptives, menopausal hormone therapy, age at menarche and menopause, pregnancies, and breastfeeding duration. The main outcomes focus on comparing these estrogen-related factors between the two tumor size groups. This observational study will help clarify links between estrogen exposure and prolactinoma size.
CONDITIONS
Brief Title
How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients aged 18 years or older at recruitment
- Diagnosis of prolactin-secreting macroadenoma made between January 2013 and December 2023, with follow-up at Hospices Civils de Lyon
- Diagnosis confirmed by MRI showing adenoma larger than 10 mm and serum prolactin levels above 100 µg/L or confirmed by response to therapy or surgery
- Ability to understand the study and give informed non-opposition
- Female patients aged 18 years or older at recruitment
- Diagnosis of prolactin-secreting microadenoma made between January 2013 and December 2023, with follow-up at Hôpital Louis Pradel
- Diagnosis confirmed by MRI showing adenoma smaller than 10 mm and serum prolactin levels above 24 µg/L without conditions affecting results
- Ability to understand the study and provide informed non-opposition
You will not qualify if you...
- Presence of a non-secreting macroadenoma
- History of isolated hyperprolactinemia or pituitary lesion before 2013 without confirmed prolactinoma diagnosis
- Known genetic abnormality or syndrome predisposing to prolactin-secreting adenoma
- Presence of a non-secreting microadenoma
- Uncertain adenoma diagnosis with ongoing treatment trial
- Isolated hyperprolactinemia without adenoma evidence
- Hyperprolactinemia or pituitary lesion without hyperprolactinemia documented prior to 2013 without confirmed diagnosis
- Known genetic abnormalities or syndromes predisposing to prolactin-secreting adenomas
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit (in-person or remote)
Duration - Varies based on medical record availability
Participants undergo assessment to confirm prolactin-secreting macroadenoma or microadenoma diagnosis through MRI and serum prolactin measurements.
No additional visits if records are sufficient; otherwise 1 visit for questionnaire administration
Duration - Up to 2 months for questionnaire completion
Participants provide detailed information on estrogen exposure and reproductive history via standardized questionnaire administered mostly by telephone or mail.
1 to 2 contacts depending on questionnaire administration method
Trial Site Locations
Total: 1 location
1
Hopital Louis Pradel
Bron, Rhone, France, 69500
Actively Recruiting
Research Team
G
Gerald RAVEROT, Pr
M
Mathilde BLARY
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here